Piclidenoson not checked
Can-Fite BioPharma · CF101
FollowEvery change as it happens, and a Monday email
Trials
3 active
11 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Piclidenoson is a selective A3AR agonist, supplied as tablets.”In the company’s words, NCT06643260 on ClinicalTrials.gov
- Tested for
- Plaque Psoriasis, Lowe Syndrome
- Main trialPhase 3
- “This is a double-blind, placebo-controlled study in adults with a diagnosis of moderate-to-severe chronic plaque psoriasis to test the efficacy and safety of piclidenoson in this patient population.”In the company’s words, NCT06643260 on ClinicalTrials.gov
- Other names
- CF101 · IB-MECA
Other drugs for Plaque Psoriasis
- ZasocitinibTakeda · Phase 3
- TQH3906Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- Total coumarin creamPsoriasis Research Institute of Guangzhou · Phase 3
- RisankizumabAbbVie · Phase 3
- PonesimodVanda Pharmaceuticals · Actelion · Phase 3
Coming up2
- 31 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Dec 2027 | A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy | |
| Phase 2Not yet recruiting | 31 Aug 2027 | An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome | |
| Phase 3Completed | Nov 2013 | Trial of CF101 to Treat Patients With Dry Eye Disease | |
| Phase 3Completed | 6 Jan 2022 | CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis | |
| Phase 2Completed | Apr 2007 | Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients | |
| Phase 2Completed | May 2009 | Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca | |
| Phase 2Completed | Sep 2009 | Safety and Efficacy Study of CF101 to Treat Psoriasis | |
| Phase 2Completed | Dec 2013 | Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis | |
| Phase 2Completed | Dec 2016 | Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure | |
| Phase 2Completed | 6 Mar 2022 | Piclidenoson for Treatment of COVID-19 | |
| Phase 2Authorised | not given | An open-label, phase 2 pilot study on the efficacy and safety of Piclidenoson in patients with Lowe syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026